GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

Hulu's ‘The Handmaid's Tale’ is based on author Margaret Atwood's book of the same name — but how similar are they?

The Season 5 finale of The Handmaid's Tale left off on a truly wild cliffhanger, which is why the wait for new episodes has ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...